Institute for Precision Medicine

A new artificial intelligence approach by Weill Cornell Medicine investigators can identify with a great degree of accuracy whether a 5-day-old, in vitro fertilized human embryo has a high potential to progress to a successful pregnancy. 

The deletion of a gene that normally promotes healthy cell division in the prostate encourages the growth of cancer in the gland, according to a new study by Weill Cornell Medicine investigators. The findings, published March 28 in Cancer Cell, suggest that the gene, once deleted, helps to promote tumorous growth.

Dr. Manuel Hidalgo, a leading physician-scientist who specializes in pancreatic cancer and drug development, has been named chief of the Division of Hematology and Medical Oncology in the Weill Department of Medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, effective June 1. 

Dr. Massimo Loda Appointed Chair of the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine and Pathologist-in-Chief at NewYork-Presbyterian/Weill Cornell Medical Center

Gene mutations detected in blood may predict risk of one of the most common forms of adult leukemia a decade before patients are diagnosed with the disease, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian investigators.

The complex life cycle of the parasite that causes malaria has made it a difficult foe to beat. But new insights on how the parasite is transmitted from humans to the mosquitoes that spread malaria may lead to new ways to control this deadly disease.

Dr. Olivier Elemento, a renowned computational biologist and leader in the field of computational genomics and biomedicine, has been named director of the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine.

Weill Cornell Medicine has been awarded a five-year, $11.3 million Specialized Programs of Research Excellence grant from the National Cancer Institute to improve the detection, diagnosis and treatment of prostate cancer. 

Growing up in Knoxville, Tennessee, Neel Madhukar always assumed he would become a physician.

To further realize the promise of precision medicine, Igor Tulchinsky, through WorldQuant, LLC, has made a $5 million gift to Weill Cornell Medicine. 

Combining genetic information from a patient’s tumor cells with three-dimensional cell cultures grown from these tumors and rapidly screening approved drugs can identify the best treatment approaches in patients for whom multiple therapies have failed.

A newly discovered genetic mutation that is found in a subtype of prostate cancer is integral to the disease’s development and growth.

Weill Cornell Medicine researchers will receive a grant from the Department of Defense to conduct an in-...

Weill Cornell Medicine (WCM) and the New York Genome Center (NYGC) were...

Study provides a framework for understanding the biological basis for chemotherapy resistance in bladder cancer.

Weill Cornell Medicine and Columbia University Medical Center, in collaboration with NewYork-Presbyterian and NYC...

A new computational approach enables researchers to predict the odds of experimental drugs succeeding in clinical trials.

A powerful next-generation genome-sequencing test developed at Weill Cornell Medicine can detect mutations that guide precision cancer treatment with over 95 percent accuracy.

Researchers from Weill Cornell Medicine, Columbia University Medical Center, NewYork-Presbyterian and NYC Health + Hospitals/Harlem seek to extend the success of precision medicine in cancer to a broad range of diseases.

The steroid dexamethasone could potentially deter the growth of a prostate cancer subtype that was previously thought to be difficult to treat with medications.